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Abstract
Xeroderma Pigmentosum (XP) is a rare inherited skin malignancy with no causative treatment options. Reporting a 23-year-old woman with xeroderma pigmentosum
who underwent several surgical tumor removals followed by further five procedures to apply tissue expander, facial resurfacing using full-thickness skin grafts with a
donor from abdominal. The next series was tumor resection in the chin, forehead, nasal reconstruction, tumor removal on bilateral third digits, and defect closure. No
recurrence after nine years of postoperative monitoring with an aesthetically acceptable result.
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Introduction
Xeroderma pigmentosum (XP) is a rare irreversible genetic disorder
caused by defective DNA repair from damage attributable to ultraviolet
(UV) light. Exposure to sunlight often causes dry skin (xeroderma) and
skin color changes (pigmentation) in affected individuals. The genetic
abnormality may accumulate and be uncorrected. According to Kleijer
et al., the prevalence of XP in American and European countries was
around 1: 1,000,000.1-3 There is no guideline in the treatment of the
abnormality due to difficulties in conducting controlled studies with the
small number of cases. However, some studies suggest that surgical
intervention must always be considered the first-line treatment in a
cutaneous tumor and replacing the entire surface of the facial skin with
skin that is unexposed to sunlight, such as the skin on the abdomen or
buttocks.4-7
This article reports a case of XP patient manifested as squamous cell
carcinoma (SCC) transitioned to basal cell carcinoma (BCC) managed
by tumor excision and facial surface resurfacing with skin grafting with
the autologous full-thickness skin graft (FTSG). After nine years
postoperatively, no recurrence of skin tumor, graft rejection, or clinical
signs of metastasis. This report discussed the contributing factors to the
recurrence of this skin malignancy based on studies, showing the
beneficial effects of surgeries to prevent tumor recurrence.
Case illustration
A 23-year-old female with xeroderma pigmentosum was admitted on
postoperative control following tumor removals and reconstructions.
Historically, when she was three months old, she had reddish spots
throughout her body. The spots darkened when it exposed directly to
sunlight. In 2008, when she was 12 years old, a lump appeared on the
nose representing an enlarged nose. Over time, the lesions grew to be

more abundant up to 4x14x0.5 cm in the largest– and 1x2x0.5 cm in the
smallest size.
On the physical examination, the eyes were shown hyperaemic.
Generalized black-red maculopapular lesions were found all over the
body, no signs of metastasis or neurological symptoms were found. The
working diagnosis was squamous cell carcinoma with suspicion of XP.

Figure 1. Anterior and lateral view case with skin malignancy before surgery.

Further investigations showed normal laboratory findings. CT scan
showed the extension of the left dorsal nasal lesion into the anterior wall
of the left maxillary sinus. The histopathology findings revealed
disparate results over multiple tests. The tumor on the nose and cheek
was surgically resected in 2010. Histopathology showed a welldifferentiated, keratinized squamous cell carcinoma with an unclean
surgical margin. In 2012, another histopathology finding confirmed XP
diagnosis with epithelial cells suggestive for basal cell carcinoma.
Another histopathology finding in 2014 confirmed an XP with basal cell
carcinoma. Finally, in 2017, histopathology showed a basal cell
carcinoma with a tumor-free surgical margin.
She had received six surgical procedures in nine years (2010 to 2019),
namely, surgical removal of squamous cell carcinoma in the nose,
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cheeks, and both hands, insertion of tissue expander in the abdominal
region, forehead, and chin, facial resurfacing with FTSG with the donor
in the abdominal, and nasal reconstruction. She did not receive any
chemotherapy or radiotherapy afterward. The following procedure was
the surgical release of symblepharon of the right eye, and the defect was
covered with lip mucosal skin grafts.

Figure 2. Tumor removal on nasal and cheeks (left) and following skin grafting
(right).

Figure 3. Nine years follow–up showed no recurrence of malignancy.

Some studies showed that basal cell carcinoma in XP was more
common at a younger age, and recurrence was more prevalent in regions
with more lesions than non-XP.10 It was contradictory with this reported
case. This case earlier was squamous cell carcinoma and changed to
basal cell carcinoma within years. She underwent surgery for basal cell
carcinoma of the face with a donor autograft from the abdomen using
the full-thickness skin graft method and found no recurrence.
Generally, in defects covered using the autograft, the malignancy may
be redeveloped, particularly those exposed to sunlight or other rays that
may elicit DNA damage on the tumor site. The skin cells in XP are
unable to repair damaged NER genes. Thus, allografts from an average
skin person will have a lower recurrence than autografts.10 With the
application of the full-thickness skin graft, this report represented a
better-healed wound based on skin grafting theory. The full-thickness
skin graft may control the development of the tumor, and the skin
structure provides more normal skin constituents. In addition, a fullthickness skin graft is more durable and aesthetically beneficial as it has
a skin color that matches the slight changes in pigmentation. Thus, the
donor area remains well lubricated from its natural sebaceous and sweat
glands.
Some reports by Ozmen et al., Agrawal et al., Atabay et al., and
Yosipovitch et al., showing no recurrence within an average of two to
four years than those reported by Ergűn et al. and Ashall et al. The last
reports showed a high recurrence rate despite the use of full-thickness
skin graft.11-16 This prompted other factors to be understood to prevent
recurrence in XP. Ergűn et al. showed that donor selection was essential
for the outcome. Thus, the donor should be in an area free of
pigmentation and less exposed to sunlight.15 This is crucial because the
XP skin exposed to extreme sunlight was more susceptible to damage to
genes, providing an unsuitable for a donor purpose. Exposure to light
with halogen sources, halides, or fluorescence must also be avoided if an
area were addressed to be used as a donor.9 The donor can be retaken
after a complete reepithelialization. Epithelial cells migrate from the
remaining hair follicles, sebaceous glands, and sweat glands left in the
dermis layer, which generally occurs within seven to ten days; some
cases require up to 21 days depending on the patient's age and nutritional
status.17

Surgical management remains the first method of treatment in XP
manifested with malignancy in the skin. The surgical procedure includes
resurfacing with different methods: dermatome shaving followed by
dermabrasion and split-thickness skin grafts, partial-thickness skin
grafts, full-thickness skin grafts, and sensate-free vascularize fascia–
cutaneous radial forearm flaps.3,8

Basal cell carcinoma is an aggressive type of cancer with a high
recurrence rate, albeit not as aggressive as malignant melanoma. A study
by Yosipovitch reported XP manifested with malignancy, namely basal
cell carcinoma and malignant melanoma treated with radical tumor
excision followed by radiotherapy. No recurrence was reported for up to
five years of monitoring. However, other tumors developed from
another region that had not been surgically removed during the
monitoring period.14 This is in line with this reported case, in which no
recurrence within nine years of postoperative monitoring.

They were principally resurfacing to place new tissue or skin strands
from regions less exposed to sunlight. The donor skin graft may be
autograft or allograft. All studies used skin grafts (autografts) to cover
defects after XP. Still, Amin et al. reported using radial forearm free flap
(i.e., a sensate-free vascularize fasciocutaneous radial forearm free flap)
with a donor from an ABO compatible mother to her five-year-old child
with XP.9 The flap survived in early postoperative days, and the wound
heals gradually. But, in the next two weeks, reddish spots appeared on
the flap where the biopsy was taken and showed a minimal
immunological reaction. Skin rejection was an issue found on the face
at the flap site, even with an immunosuppressant. The affected site was
retreated surgically using a partial thickness skin graft, and the tumor
recurred after ten months.9

Yosipovitch et al. showed that the autograft used, and defects have the
same DNA properties as those of the recipient's body, as previously
mentioned. However, those did not regrow into skin malignancy even
after sun exposure.14 This may be due to underlying differences of
malignancy in subjects with and without XP. A study showed that XP
encountered issues of abnormal cellular-level immunity and delayed
hypersensitivity. The study also showed the impaired proliferative
response of lymphocytes against mitogens and decreased NK cell
activity. Immunohistochemical staining showed complete infiltration of
CD163+ M2 macrophages along with regulatory Foxp3+ T cells.18
Nonetheless, there are yet studies to accurately determine lymphocyte
profiles in XP. With more studies, the medical world can find an
allograft for XP patients to improve their quality of life and survival.

Discussion
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The prognosis includes the association of climate differences in
countries with XP cases, unavailability of a simple detection method, no
detailed profile of lymphocytes in XP, and the lack of updated surgical
techniques and adequacy in excision. To date, full-thickness skin grafts
remain the method to treat the skin defect after XP removal.
Conclusions

6.

Even without adjunct therapy, precise surgery yielding surgical free
margin could achieve remission in XP. Choice of donor types and usage
of FTSG yields favorable results regarding malignancy control.
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